Study shows sample-drug adherence link

Share this article:
Study shows sample-drug adherence link
Study shows sample-drug adherence link

Adding more to the prescription adherence/non-adherence data field is a study by the University of Pittsburgh School of Pharmacy's Program Evaluation Research Unit that found that handing a patient a free 30-day prescription increased the likelihood that a pharmacy fill would follow.

MedVantx, which has an e-prescription service, funded the study which compared fill rates among patients covered by one of two health plans. These two groups were divided into control groups which received prescriptions but no samples, and test groups, which received free 30-day samples in addition to prescriptions.

In short: a patient who left the doctor's office with a 30-day drug supply was more likely to fill their prescription. Further, a patient who pocketed a free sample when leaving the doctor's office also had a higher rate of subsequent refills, at 59.8%, compared to the 48.9% of non-samplers who sought out a second refill. After 90 days, samplers had 42% more medicated days than their peers. Samplers also had 15% more medicated days than their sample-free peers at the 180-day mark.

Like many adherence studies, this one did not run long enough to provide insight as to what this means in terms of long-term savings, such as those associated with preventing or delaying the onset of co-morbid conditions that typically follow patients with conditions such as diabetes, high blood pressure or high cholesterol. Nor does it show a reduced use of intense—also known as pricey—medical interventions. However, researchers did find slightly lower healthcare costs among patients who received samples.

The researchers touch on a thread that surfaced in a Merck-supported study about asthma adherence: side effects, and the possibility that samples may have eased pre-medication concerns.

Additional reasons for lack of medication adherence include cost and convenience.

Share this article:

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.